These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture. Unterfrauner M; Rejeski HA; Hartz A; Bohlscheid S; Baudrexler T; Feng X; Rackl E; Li L; Rank A; Filippini Velázquez G; Schmid C; Schmohl J; Bojko P; Schmetzer H Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139264 [TBL] [Abstract][Full Text] [Related]
3. Effective and Successful Quantification of Leukemia-Specific Immune Cells in AML Patients' Blood or Culture, Focusing on Intracellular Cytokine and Degranulation Assays. Schutti O; Klauer L; Baudrexler T; Burkert F; Schmohl J; Hentrich M; Bojko P; Kraemer D; Rank A; Schmid C; Schmetzer H Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000091 [TBL] [Abstract][Full Text] [Related]
4. Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes. Rackl E; Li L; Klauer LK; Ugur S; Pepeldjiyska E; Seidel CL; Gunsilius C; Weinmann M; Doraneh-Gard F; Reiter N; Plett C; Amberger DC; Bojko P; Kraemer D; Schmohl J; Rank A; Schmid C; Schmetzer HM Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613907 [TBL] [Abstract][Full Text] [Related]
5. Volatile Phases Derived from Serum, DC, or MLC Culture Supernatants to Deduce a VOC-Based Diagnostic Profiling Strategy for Leukemic Diseases. Baudrexler T; Boeselt T; Li L; Bohlscheid S; Boas U; Schmid C; Rank A; Schmohl J; Koczulla R; Schmetzer HM Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371569 [TBL] [Abstract][Full Text] [Related]
6. Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro. Klauer LK; Schutti O; Ugur S; Doraneh-Gard F; Amberger DC; Rogers N; Krämer D; Rank A; Schmid C; Eiz-Vesper B; Schmetzer HM Transfus Med Hemother; 2022 Feb; 49(1):44-61. PubMed ID: 35221867 [TBL] [Abstract][Full Text] [Related]
7. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions. Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655 [TBL] [Abstract][Full Text] [Related]
10. Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations. Schick J; Vogt V; Zerwes M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H J Immunother; 2013 May; 36(4):223-37. PubMed ID: 23603857 [TBL] [Abstract][Full Text] [Related]
11. Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on Dendritic cells of leukemic origin (DC Ansprenger C; Amberger DC; Schmetzer HM Clin Immunol; 2020 Aug; 217():108467. PubMed ID: 32464186 [TBL] [Abstract][Full Text] [Related]